About us

Antibody microarray with spots lined up in antibody form 

Sciomics – Antibody meets microarray

Sciomics GmbH was founded in the spring of 2013 as a spin-off company of the German Cancer Research Center (DKFZ) by Dr. Christoph Schröder and Dr. Jörg Hoheisel. Since 2003, our team has gained experience with production and application of antibody microarrays as a tool for analysing complex protein samples. With this background, Sciomics is able to offer complete analysis of your samples with standardised as well as customised arrays.

 

Analyse your protein sets of interest

Antibody microarrays make it possible to analyse complete signalling pathways, up- or downstream elements of your protein of interest or hits from next generation sequencing for their impact on protein level. Such an analysis requires only very small sample volumes, as little as 15µL of blood plasma, for example. This facilitates a robust and multiplex analysis of plasma or tissue proteins not only from human but also from small experimental animals such as the murine samples. We offer standardised arrays or produce customised arrays for your list of targets or with your selection of antibodies.

Based on more than a decade of experience in profiling studies with antibody microarrays, we also offer a complete analysis service including protein extraction from plasma, serum, tissue or cell culture samples, sample labelling and incubation as well as the subsequent data analysis.

 

Identification of protein biomarker signaturesTypical results for a highly parallel protein analyses with antibody microarrays

In addition to their application for profiling studies, antibody microarrays are a valuable tool for the identification or verification of potential protein biomarkers. Based on analyses using complex antibody microarrays, biomarker signatures were identified for a prognosis in bladder cancer and a diagnosis of pancreatic cancer. These are currently being validated in larger scale studies.

Contact us to learn more about the potential of complex antibody microarrays for your protein biomarker screening or verification study.

 

 

Do you like to subscribe our newsletter ?      Yes   No

Our service portfolio

scioPhospho: protein profiling and phosphorylation status

scioPhospho: protein profiling and phosphorylation status

scioPhospho combines the advantages of a robust and cost-efficient protein expression profiling using scioDiscover with information on phosphorylation status. This combination provides a comprehensive overview on signalling events and pathway activity regulation. Features 1030 highly relevant proteins are profiled in a single assay Phosphorylation status combined with protein expression levels Tyrosine,…
Read more
scioDiscover - Protein Profiling on expression level

scioDiscover - Protein Profiling on expression level

Knowledge about protein expression levels is of utmost importance to predict toxic effects, estimate adverse effects of drug candidates and to identify new drug targets. Sciomics has a highly optimised…
scioCD - Cell surface marker and Cytokine profiling

scioCD - Cell surface marker and Cytokine profiling

  Characterise a certain cell type?   Cell composition in a certain tissue sample?   In-depth profiling of CD-marker expression?   Increase your throughput at high sensitivity levels? You aim…
scioUbi

scioUbi

Protein & ubiquitination profiling scioUbi is a high-content protein expression and ubiquitination level analysis. With scioUbi you can analyse up to 1,000 proteins in a single assay.   Features Ubiquitination…
scioCyto

scioCyto

Cytokine profiling scioCyto is a high-content analysis service for cytokine and chemokine profiling on protein level. A great variety of samples such as plasma, tissue, cells or cell cultur supernatants…

News

New article | Activated Eosinophils Exert Antitumorigenic Activities in Colorectal Cancer

| Jan 2019 | In the article, scientists at Tel Aviv University used our scioDiscover platform to analyse tumor-associated eosinophils in colorectal cancer. The full article is published in Cancer Immunology Research.

 

New article | Macrophage-derived IL-1β and TNF-α regulate arginine metabolism in neuroblastoma

| Decembre 2018 | Study by our collaborator Dr Francis Mussai at University of Birmingham suggests arginine metabolism as a target for neuroblastoma therapy. At Sciomics we are proud of having contributed to this exciting study by a scioDiscover protein profiling study. The article is published in Cancer Research.

 

New article | Protection from ischemia reperfusion injury-induced inflammation and fibrosis in C5aR2-deficient mice

| June 2018 | Complement component 5a receptor 2 (C5AR2) deficient mice are protected from inflammation and fibrosis in response to ischemia reperfusion injury. Our scioPhospho platform supported scientists at the Medical School Hannover to elucidate the underlying mechanism. The data were recently published in Kidney International.

 

New article | Modeling Congenital Adrenal Hyperplasia and Testing Interventions for Adrenal Insufficiency Using Donor-Specific Reprogrammed Cells

| January 2018 | A scioDiscover protein microarray study contributed to an article in Cell Reports. In this study Gerard Ruiz-Babot et al. analysed a donor specific reprogramming of cells.

Customer testimonial Leonardo Guasti, PhD (senior author):

This has undoubtedly opened new avenues in our research. We have found the Sciomics team to be extremely helpful and efficient during the whole process, from advising the best strategy to the final interpretation of results.

> More testimonials

A glas full of hope | Ein Glas Hoffnung

| January 2018 | Article on the StartUp Sciomics and our antibody microarray platform by our partner SCHOTT nexterion.

> English version "A glass full of hope"

> Deutsche Version "Ein Glas Hoffnung"

Tweets

  • 4 days ago

    RT @MCDS_Therapy: Fantastic news - we are now halfway to reaching our recruitment target in the UK! 🙌 Recruitment will continue at our two…

  • 7 days ago

    RT @MCDS_Therapy: Huge congratulations to the @AKUSociety on the positive outcomes of their #DrugRepurposing clinical trial 👏 We are using…

  • 10 days ago

    RT @MCDS_Therapy: Recruitment into our #ClinicalTrial is coming along nicely and we have now got 5 participants registered in the UK! 🙌 R…

  • 13 days ago

    RT @BioRNCluster: 🗣️#BioRNMember @sciomics has two open positions: one lab technician and one team assistant. Spread the word! Sciomics - E…

  • 23 days ago

    RT @MCDS_Therapy: #DrugRepurposing is significantly faster and cheaper than conventional drug discovery. This is why we are using it in our…